NCT04271644View on ClinicalTrials.gov

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

July 1, 2027

Conditions
Multiple MyelomaNeoplasm, Plasma CellMultiple Myeloma in Relapse
Interventions
BIOLOGICAL

BCMA CAR-T cells

BCMA CAR-T cell therapy

Trial Locations (1)

Unknown

RECRUITING

920th Hospital of Joint Logistics Support Force, Kunming

All Listed Sponsors
lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY